<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919633</url>
  </required_header>
  <id_info>
    <org_study_id>4316001</org_study_id>
    <nct_id>NCT00919633</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C</brief_title>
  <acronym>COPE-HCV</acronym>
  <official_title>COPE-HCV: Continuous Interferon Delivery Via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Corporate Technologies and New Ventures</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Corporate Technologies and New Ventures</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon
      alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a
      safe and effective treatment for patients with chronic hepatitis C infection as compared to
      patients who receive standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients who are diagnosed with chronic hepatitis C genotype 1
      infection and who have received no previous interferon or other anti-HCV treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Load: Incidence of Sustained Virologic Response (SVR)</measure>
    <time_frame>24 weeks after treatment is complete</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Tolerability</measure>
    <time_frame>Through study week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid Virologic Response (RVR)</measure>
    <time_frame>Study Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Virologic Response (EVR)</measure>
    <time_frame>Study week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-of-treatment Response (EOT)</measure>
    <time_frame>Study week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>through Study Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>through Study Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Health, Depression Score, and Fatigue Level</measure>
    <time_frame>through Study Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Decay</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous subcutaneous infusion for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous subcutaneous infusion for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous subcutaneous infusion for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: peginterferon alfa-2b (1.5 μg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous weekly for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alfa-2b</intervention_name>
    <description>subcutaneous continuous infusion at one of three doses for 48 weeks</description>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <other_name>INTRON® A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2b</intervention_name>
    <description>1.5 μg/kg subcutaneous weekly for 48 weeks</description>
    <arm_group_label>Group 4: peginterferon alfa-2b (1.5 μg/kg)</arm_group_label>
    <other_name>PEGINTRON™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin, USP</intervention_name>
    <description>All patients will receive oral ribavirin</description>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <arm_group_label>Group 4: peginterferon alfa-2b (1.5 μg/kg)</arm_group_label>
    <other_name>Rebetol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>external drug infusion pump</intervention_name>
    <description>pump delivery system for continuous subcutaneous infusion of interferon alfa-2b</description>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <other_name>Medtronic MiniMed™ Paradigm® Insulin Pump Infusion System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed patient consent form

          -  Genotype 1 chronic HCV with detectable HCV RNA

          -  No previous treatment for HCV infection

          -  Hepatitis B and human immunodeficiency virus negative at screening visit

          -  Able and willing to follow contraception requirements

          -  Screening laboratory values, test, and physical exam within acceptable ranges

          -  Weight between 40 kg and 125 kg

          -  Proficiency in the use of the external pump infusion system

        Exclusion Criteria:

          -  Current or planned enrollment in another investigational device or drug study

          -  Anticipated inability to complete all clinic visits and comply with study procedures

          -  History of, or any current medical condition, which could impact the safety of the
             subject during the study

          -  Autoimmune hepatitis, suspected hepatocellular carcinoma, decompensated liver disease,
             or other known liver disease other than HCV

          -  Alcoholism or substance abuse with &lt;6 documented months of sobriety

          -  Known allergy or sensitivity to interferons or ribavirin

          -  Any other condition that, in the opinion of the Investigator, would make the subject
             unsuitable for enrollment or could interfere with the subject participating in and
             completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Muir, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Mische, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Ventures and New Therapies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html</url>
    <description>Viral cancers: Hepatitis C</description>
  </link>
  <link>
    <url>http://ctep.cancer.gov</url>
    <description>Common terminology criteria for adverse events, version 3.0</description>
  </link>
  <link>
    <url>http://www.ICMJE.org</url>
    <description>International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. Publication ethics: sponsorship, authorship and accountability.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>March 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2014</results_first_posted>
  <last_update_submitted>March 28, 2014</last_update_submitted>
  <last_update_submitted_qc>March 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>genotype</keyword>
  <keyword>sustained virological response</keyword>
  <keyword>rapid virological response</keyword>
  <keyword>interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment 09-Jun-2009, final subject complete 19-Jun-2012.</recruitment_details>
      <pre_assignment_details>210 screened, 116 randomized, 106 received at least 1 dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 4: Peginterferon Alfa-2b (1.5 μg/kg)</title>
          <description>subcutaneous weekly for 48 weeks
peginterferon alfa-2b : 1.5 μg/kg subcutaneous weekly for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="P2">
          <title>Group 1: Interferon Alfa-2b (Dose 1)</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="P3">
          <title>Group 2: Interferon Alfa-2b (Dose 2)</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="P4">
          <title>Group 3: Interferon Alfa-2b (Dose 3)</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdraw consent post transition to SOC</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Request of withdrawal w/o future contact</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Viral rebound outside protocol timepoint</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 4: Peginterferon Alfa-2b (1.5 μg/kg)</title>
          <description>subcutaneous weekly for 48 weeks
peginterferon alfa-2b : 1.5 μg/kg subcutaneous weekly for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="B2">
          <title>Group 1: Interferon Alfa-2b (Dose 1)</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="B3">
          <title>Group 2: Interferon Alfa-2b (Dose 2)</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="B4">
          <title>Group 3: Interferon Alfa-2b (Dose 3)</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" lower_limit="48.5" upper_limit="53.8"/>
                    <measurement group_id="B2" value="51.5" lower_limit="47.0" upper_limit="56.1"/>
                    <measurement group_id="B3" value="51.3" lower_limit="46.7" upper_limit="55.5"/>
                    <measurement group_id="B4" value="49.1" lower_limit="44.6" upper_limit="53.2"/>
                    <measurement group_id="B5" value="51.2" lower_limit="44.6" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C Genotype</title>
          <description>1a, 1b</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Viral Load: Incidence of Sustained Virologic Response (SVR)</title>
        <time_frame>24 weeks after treatment is complete</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Peginterferon Alfa-2b (1.5 μg/kg)</title>
            <description>subcutaneous weekly for 48 weeks
peginterferon alfa-2b : 1.5 μg/kg subcutaneous weekly for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Interferon Alfa-2b (Dose 1)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Interferon Alfa-2b (Dose 2)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O4">
            <title>Group 3: Interferon Alfa-2b (Dose 3)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load: Incidence of Sustained Virologic Response (SVR)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety/Tolerability</title>
        <time_frame>Through study week 72</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rapid Virologic Response (RVR)</title>
        <time_frame>Study Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Peginterferon Alfa-2b (1.5 μg/kg)</title>
            <description>subcutaneous weekly for 48 weeks
peginterferon alfa-2b : 1.5 μg/kg subcutaneous weekly for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Interferon Alfa-2b (Dose 1)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Interferon Alfa-2b (Dose 2)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O4">
            <title>Group 3: Interferon Alfa-2b (Dose 3)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Virologic Response (RVR)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Virologic Response (EVR)</title>
        <time_frame>Study week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 4: Peginterferon Alfa-2b (1.5 μg/kg)</title>
            <description>subcutaneous weekly for 48 weeks
peginterferon alfa-2b : 1.5 μg/kg subcutaneous weekly for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O2">
            <title>Group 1: Interferon Alfa-2b (Dose 1)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O3">
            <title>Group 2: Interferon Alfa-2b (Dose 2)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
          <group group_id="O4">
            <title>Group 3: Interferon Alfa-2b (Dose 3)</title>
            <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Early Virologic Response (EVR)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-of-treatment Response (EOT)</title>
        <time_frame>Study week 48</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics</title>
        <time_frame>through Study Week 72</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics</title>
        <time_frame>through Study Week 72</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Health, Depression Score, and Fatigue Level</title>
        <time_frame>through Study Week 72</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Decay</title>
        <time_frame>12 weeks of treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected the duration of the study from activation to closure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PEGINTRON 1.5</title>
          <description>subcutaneous weekly for 48 weeks
peginterferon alfa-2b : 1.5 μg/kg subcutaneous weekly for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="E2">
          <title>INTRON A 80,000</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="E3">
          <title>INTRON A 120,000</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
        <group group_id="E4">
          <title>INTRON A 160,000</title>
          <description>continuous subcutaneous infusion for 48 weeks
external drug infusion pump : pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
interferon alfa-2b : subcutaneous continuous infusion at one of three doses for 48 weeks
ribavirin, USP : All patients will receive oral ribavirin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypertensive Heart Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection Site Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Staphylococcal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pneumonia Moraxella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Streptococcal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Techycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Retinal Exudates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gingival Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Uric Acid Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="27"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Libido Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Trial Manager</name_or_title>
      <organization>Medtronic, Inc.</organization>
      <phone>763-505-4594</phone>
      <email>sarah.mische@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

